AstraZeneca to Invest $90-Mn in India over Next 5 Years
Biopharmaceutical firm AstraZeneca has revealed plans to invest $90-mn (around Rs. 590-crore) in India over the next five years. The announcement followed the signing of a bilateral innovation partnership for a sustainable future between Sweden and India.
“Our latest investment reflects our commitment to address the unmet needs in non-communicable diseases, enable high-value job creation and boost medical innovation in the country,” AstraZeneca Executive VP for International Region Mr. Leon Wang said.
AstraZeneca said the investment will be targeted at strengthening manufacturing, clinical operations, patient safety & regulatory science, IT services and commercial operations.
The company believes, this investment commitment across AstraZeneca’s business footprint in India will make a positive impact. It also aligns closely with the government’s vision for healthcare and innovation, Mr. Wang said.
You May Interested In
Glow70/KLOW80 99% China Peptides Warehouse Direct Delivery Lyophilized Powder in Stock
$1.8E+2/UNIT FOB
2026-08-16
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
AstraZeneca Pays Up to $1.5 Billion for Global Rights to Chinese Lung Cancer Drug
-
AstraZeneca’s Wainua Fails Phase III Heart Trial, Wiping Out About $27 Billion in Market Value
-
$15 Billion Invested in China: AstraZeneca Builds an “Innovation Hub” While Some Are Still Waiting for the Windfall
-
AstraZeneca to Invest $2 Billion in New U.S. Biologics Facilities
-
AstraZeneca to Invest $2.5 Billion to Establish Global Drug R&D Center in Beijing
-
AstraZeneca to invest $3.5 billion in the United States
-
Ascending to the Summit: AstraZeneca Crowned as the Most Competitive MNC in China
-
Restructuring at AstraZeneca China: Leadership Changes and New Business Division
-
Bristol Myers Squibb's Acquisition Spree: Will it Boost its Cancer Drug Portfolio?
-
Is AstraZeneca's Acquisition of Gracell Biotechnologies a Game-Changer for Cell Therapy and Expansion in China?
Recommend Reading
-
L Catterton to Acquire Minority Stake in Perfume Company EX NIHILO
-
Europe’s Chemical Industry Sounds the “Shutdown Alarm”: It’s Not Just a Few Plants at Risk—The Entire Industrial Chain Is Shaking
-
Sinochem International Acquires Nantong Xingchen for 2.11 Billion Yuan, Rike Chemical Plans Genyuan New Materials Acquisition – The Changing Landscape of Chemical M&A
-
A $25 Billion “Mega Merger” Is Born: How the AkzoNobel × Axalta Deal Rewrites Global Coatings Power
-
Haldia Petrochemicals Pipeline Fire in India Adds Uncertainty to Asia's Naphtha Market
-
Premium Global Chemical Sourcing Requests (15-19 Dec 2025)
-
International Oil Prices Experience a "Heart-Stopping Day" as U.S.-Iran Tensions Trigger Massive Shockwaves in the Energy Market
-
Following Cost Fluctuations, Polyester Staple Fiber Prices in China Adjusted Weaker in August
-
Mid-January Acetic Acid Market Trends Show a Strong Uptrend
-
Supply Strong, Demand Weak: ABS Continues to Fall in August